PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer

Background Immune checkpoint inhibitors have improved outcomes for several malignancies; however, there remains a lack of accurate, non-invasive methods to assess tumor PD-L1 expression levels and guide immunotherapy. This study aimed to evaluate the role of PD-L1-targeted positron emission tomography (PET) imaging in predicting immunotherapy response and prognosis in lung cancer. Methods Four healthy volunteers and 22 treatment-naïve lung cancer patients were prospectively enrolled and underwent 68 GaGa-PDL1p PET imaging. All patients additionally completed paired baseline 18 Ffluorodeoxyglucose ( 18 FFDG) PET scans. Of the 22 patients, 17 received ≥3 cycles of immunotherapy combined with chemotherapy and underwent follow-up 18 FFDG PET or CT examinations. The correlations of baseline 68 GaGa-PDL1p and 18 FFDG uptake with tumor PD-L1 expression were evaluated. Furthermore, the associations of tumor 68 GaGa-PDL1p uptake, 18 FFDG uptake, and PD-L1 expression with immunotherapy response were analyzed, along with their predictive values for immunotherapy efficacy and outcomes. Results Lesions with high PD-L1 expression exhibited significantly higher 68 GaGa-PDL1p uptake than those with low expression (p=0.007), whereas 18 FFDG uptake showed no significant difference (p=0.499). At baseline, 68 GaGa-PDL1p uptake was significantly higher in responders than in non-responders (p=0.008), with an area under the receiver operating characteristic curve of 0.886. In contrast, neither 18 FFDG uptake nor PD-L1 expression levels differed significantly between the two groups. Disease progression occurred in 23.5% of patients (4/17) by the final follow-up. Patients with higher 68 GaGa-PDL1p uptake or higher 18 FFDG uptake demonstrated significantly longer progression-free survival (PFS) than those with lower uptake (p=0.033 and p<0.001, respectively). However, no significant difference in PFS was observed between patients with high and low PD-L1 expression, using either a 50% (p=0.487) or 1% (p=0.100) cut-off. Conclusions 68 GaGa-PDL1p PET outperforms conventional 18 FFDG PET and immunohistochemistry-based PD-L1 assessment in predicting immunotherapy response and prognosis. These findings offer new insights for evaluating immunotherapy efficacy and guiding individualized tumor treatment.